TrialFrontiers in immunology2024

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Lourdes Hontecillas-Prieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.